Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Capecitabine in High-Risk Pseudomyxoma Peritonei (ACAPP)
NCT05321329Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2018
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in pseudomyxoma peritonei (PMP), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Status: unknown.
02
Drugs
capecitabine
03
Conditions
pseudomyxoma peritonei (PMP)
Beyond the preview
Go deeper on NCT05321329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321329.